65,437 trials
Metabolic Syndrome
Primary: Change in the Pre- and Post-treatment Systolic Blood Pressure — 129.5; 134.5; 122.6; 127.5 mm Hg
Prevention of Hair Growth
Primary: Physician's Global Assessment (PGA) of Hair Density — 1; 0; 1 participants
Obstructive Sleep Apnea Syndrome
Primary: The Primary Efficacy Variable Was the Mean Apnea-Hypopnea Index (AHI). — 22.33; 18.18; 21.10; 22.71 Apnea + Hypopnea episodes per hour — p=0.009
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Primary: National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score. — 26.0; 26.8; 27.9; -12.1 Units on a 0 to 43 scale
Candidemia
Primary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition
Crohn's Disease
Primary: Number of Participants Who Had Remission of Crohn's Disease After 8-week Treatment — 6; 7; 3 Participants
Pain · Fatigue
Primary: Short Form 36 (SF-36) Physical Component Summary (PCS) — 36.2; 39.0 Scores on a scale — p=0.487
Infertility · Ovulation Induction
Primary: Percentage of Participants With Ovulation — 79.1; 82.6 percentage of participants
Alteration of Cognitive Function · Dietary Modification
Primary: Change of Cognitive Function Measured by a Mini Mental State Examination Scores on a Scale According to Study Group — 23.3; 23.8; 23.1; 23.7 units on a scale
Smoking Cessation
Primary: Percentage of Participants Who Abstained From Smoking at Week 12 — 71.1 percentage of participants
HIV Infections
Primary: Change in CD4+ T-cell Count — 12 cells/mm^3 — p=0.97
Stroke
Primary: Number of Patients With Valid Recanalization Assessed by Magnetic Resonance Angiography (MRA) — 30; 40 participants
Mesothelioma
Primary: Best Response — 0; 7; 11; 11 participants
HIV Infections
Primary: Comparison of Virologic Response at Week 24 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population — 137; 276; 11; 19 participants
Dermatitis, Seborrheic
Primary: Number of Participants With Any Adverse Event (AE) — 282 participants